Marketing & Sales

AstraZeneca sells US, Canada rights of Seroquel drugs to Cheplapharm

AstraZeneca has signed a deal worth up to $41m to divest the US and Canada commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) to German pharma company Cheplapharm Arzneimittel.

Asahi Kasei to acquire Veloxis Pharmaceuticals for $1.3bn

Japan-based Asahi Kasei Group has signed an agreement to acquire Danish pharma company Veloxis Pharmaceuticals for DKK8.9bn ($1.3bn) in an all-cash deal.

Novartis’ Sandoz to buy Aspen’s Japanese business in $441m deal

Novartis division Sandoz has signed a binding agreement to acquire Aspen Global’s Japanese business in a deal valued at around €400m ($441m).

Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates

Samsung Bioepis Co., Ltd. announced today that it has entered into a new commercialization agreement with Biogen (Nasdaq: BIIB) for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept), in the United States (US), Canada, Europe, Japan, and Australia.

AstraZeneca to sell anti-psychotic medicine rights in Europe and Russia for $239m

AstraZeneca has signed an agreement to sell Seroquel medicine rights in Europe and Russia to Cheplapharm Arzneimittel for around $239m.

Bavarian Nordic to buy GSK’s rabies and tick-borne encephalitis vaccines

Denmark-based Bavarian Nordic has signed an agreement to acquire rabies and tick-borne encephalitis (TBE) vaccines from GlaxoSmithKline in a deal valued at around €796m ($888m).

Acino to buy Takeda’s select OTC and prescription pharmaceutical assets for $200m

Swiss pharmaceutical company Acino has agreed to acquire Takeda’s select over-the-counter (OTC) and prescription pharmaceutical assets in multiple Near East, Middle East and Africa (NEMEA) countries for a total value of more than $200m.

Servier acquires lymphoma drug Pixuvri from CTI BioPharma

French pharma company Servier has acquired cancer drug Pixuvri (pixantrone) from US-based CTI BioPharma for an undisclosed price in a move to strengthen its oncology portfolio.

Amgen to buy Celgene’s psoriasis drug Otezla for £10.9bn

US-based Amgen has agreed to acquire Celgene’s psoriasis drug Otezla (apremilast) and certain related assets and liabilities for $13.4bn (£10.9bn) in cash.